Zeptosens, a Division of Bayer (Schweiz) AG Technology Services
Development, production and marketing of innovative and highly sensitive DNA and protein microarrays
Zeptosens was founded in September 1998 as a spin-off from Novartis and has been in operation since March 1, 1999. It was taken over by Bayer Technology Services GmbH and continued the key business activities as Zeptosens, a Division of Bayer (Schweiz) AG Technology Services.
Markus Ehrat
Gerhard M. Kresbach
Benkenstrasse 254
4108 Witterswil
Switzerland
Phone: +41 61 726 81 81
Fax +41 61 726 81 71
The company’s core business is the development, production and marketing of highly-sensitive biochip systems based on fluorescence detection on the surface of a planar optical waveguide.
The ZeptoREADER(TM), the ZeptoMARK® and SensiChip(TM) product lines are all based on planar waveguide technology (PWT), which provides outstanding sensitivity and selectivity. The company’s bioassays are designed for multiplexed nucleic acid hybridisation assays, immunoaffinity reactions and membrane-receptor based assays.
Related patents
- Sampling device and its use for controlling sample introduction in microcolumn separation techniques
- Method for controlling sample introduction in microcolumn separation techniques and sampling device
- Optical detection apparatus for chemical analyses of small volumes of samples
- Optical detection device based on semi-conductor laser array
- Optical chemical/biochemical sensor
- Method for controlling sample introduction in microcolumn separation techniques and sampling device
- Sensing unit provided with separated detection light guiding
- Body for flow-through cells and the use thereof
- Kit for assay development and serial analysis